TELA Bio, Inc. (NASDAQ:TELA – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 563,300 shares, a growth of 22.6% from the December 15th total of 459,300 shares. Based on an average trading volume of 38,100 shares, the short-interest ratio is presently 14.8 days. Currently, 4.9% of the shares of the company are sold short.
Analysts Set New Price Targets
Several research analysts have recently commented on TELA shares. JMP Securities lowered their target price on shares of TELA Bio from $22.00 to $20.00 and set a “market outperform” rating on the stock in a report on Thursday, November 10th. Piper Sandler dropped their target price on shares of TELA Bio from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, November 10th.
Insider Activity at TELA Bio
In other news, major shareholder Opaleye Management Inc. acquired 20,262 shares of TELA Bio stock in a transaction on Thursday, November 3rd. The shares were purchased at an average price of $7.81 per share, with a total value of $158,246.22. Following the acquisition, the insider now owns 1,948,000 shares in the company, valued at $15,213,880. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 5.70% of the company’s stock.
Institutional Investors Weigh In On TELA Bio
TELA Bio Price Performance
Shares of NASDAQ:TELA opened at $12.00 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 4.86 and a quick ratio of 4.06. TELA Bio has a 1-year low of $5.15 and a 1-year high of $13.37. The company has a market capitalization of $229.91 million, a P/E ratio of -4.20 and a beta of 0.98. The firm’s 50 day simple moving average is $10.10 and its two-hundred day simple moving average is $8.96.
TELA Bio (NASDAQ:TELA – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). TELA Bio had a negative net margin of 112.49% and a negative return on equity of 321.48%. The firm had revenue of $11.16 million for the quarter, compared to the consensus estimate of $10.65 million. Research analysts expect that TELA Bio will post -2.74 EPS for the current fiscal year.
About TELA Bio
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
- Get a free copy of the StockNews.com research report on TELA Bio (TELA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.